Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Cancer Therapies02:49

Cancer Therapies

8.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

5.2K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
5.2K
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.3K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.

Nature cancer·2026
Same author

Divergence in poxvirus-encoded E3-like proteins can dictate poxvirus activation of cellular necroptosis.

Journal of virology·2026
Same author

Large Language Models for Summarizing Advance Care Planning Information From Goals of Care Notes in the EHR.

Learning health systems·2026
Same author

Uncovering complex phonon interactions in Mg<sub>3</sub>Bi<sub>2-x</sub>Sb<sub>x</sub>: topology and avoided crossings.

Nature communications·2026
Same author

Implementation of 2023 Canadian Thoracic Society Guidelines for Single-Inhaler Triple Therapy Could Reduce Exacerbation and Mortality Rates in COPD: PROMETHEUS Canada.

Chronic obstructive pulmonary diseases (Miami, Fla.)·2026
Same author

Poxvirus attack of antiviral defense pathways unleashes an effector-triggered NF-κB response.

Science (New York, N.Y.)·2026
Same journal

Gut commensal Bacteroides-derived pantothenic acid alleviates metabolic syndrome.

Cell host & microbe·2026
Same journal

Predicting antimicrobial resistance for precision medicine.

Cell host & microbe·2026
Same journal

Meta-analysis reveals microbiome signatures for colorectal cancer that are universal across age groups and sequencing methods.

Cell host & microbe·2026
Same journal

Single-cell detection and quantification of the microbiota by MicFLY.

Cell host & microbe·2026
Same journal

Suppression of host salicylic acid defense by a phloem-colonizing pathogen effector in citrus Huanglongbing.

Cell host & microbe·2026
Same journal

CBASS limits bacteriophage production while maintaining cell viability in Pseudomonas aeruginosa.

Cell host & microbe·2026
See all related articles

Related Experiment Video

Updated: May 2, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.1K

Viruses for tumor therapy.

John Bell1, Grant McFadden2

  • 1Center for Cancer Therapeutics, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.

Cell Host & Microbe
|March 18, 2014
PubMed
Summary
This summary is machine-generated.

Oncolytic virotherapy uses live viruses to target cancer cells, showing promise for cancer treatment. Future strategies involve combining oncolytic viruses with immune-modulating drugs to enhance antitumor responses.

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

8.9K
Ex Vivo Infection of Live Tissue with Oncolytic Viruses
12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

13.5K

Related Experiment Videos

Last Updated: May 2, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.1K
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

8.9K
Ex Vivo Infection of Live Tissue with Oncolytic Viruses
12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

13.5K

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Oncolytic virotherapy utilizes viruses to selectively infect and destroy cancer cells.
  • Clinical trials have advanced the understanding of oncolytic virus safety and efficacy.
  • Virus replication that stimulates antitumor immunity is key to successful virotherapy.

Purpose of the Study:

  • To review the progress and future directions of oncolytic virotherapy.
  • To highlight the importance of immune responses in cancer virotherapy.
  • To propose combination strategies for enhanced cancer treatment.

Main Methods:

  • Review of clinical trial data and scientific literature on oncolytic virotherapy.
  • Analysis of factors influencing oncolytic virus efficacy, particularly immune stimulation.
  • Discussion of potential combination therapies with immunomodulatory agents.

Main Results:

  • Oncolytic viruses demonstrate a favorable safety profile in clinical settings.
  • Efficacy is significantly improved when virus replication triggers sustained antitumor immunity.
  • Current research indicates a need for combination approaches to overcome immune tolerance.

Conclusions:

  • Oncolytic virotherapy is a safe and increasingly effective cancer treatment modality.
  • Stimulating robust and sustained antitumor immune responses is critical for therapeutic success.
  • Combining oncolytic viruses with immunomodulatory drugs holds significant promise for future cancer treatment.